Aytu BioScience Inc.

6.44-0.0600-0.92%Vol 381.86K1Y Perf -53.67%
Apr 20th, 2021 16:00 DELAYED
BID6.44 ASK6.46
Open6.50 Previous Close6.50
Pre-Market- After-Market-
 - -  - -%
Target Price
17.40 
Analyst Rating
Strong Buy 1.00
Potential %
170.19 
Finscreener Ranking
★★★★★     63.61
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★     56.36
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★     60.51
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap115.17M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
3.76 
Earnings Date
13th May 2021

Today's Price Range

6.276.54

52W Range

5.8621.30

5 Year PE Ratio Range

-0.4000-0.2000

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-5.57%
1 Month
-33.81%
3 Months
-18.69%
6 Months
-36.24%
1 Year
-53.67%
3 Years
-94.51%
5 Years
-99.98%
10 Years
-

TickerPriceChg.Chg.%
AYTU6.44-0.0600-0.92
AAPL133.11-1.7300-1.28
GOOG2 293.63-8.7700-0.38
MSFT258.26-0.4800-0.19
XOM55.29-1.1900-2.11
WFC42.54-1.3400-3.05
JNJ166.483.79002.33
FB302.650.41000.14
GE13.06-0.4000-2.97
JPM149.27-3.3800-2.21
Financial StrengthValueIndustryS&P 500US Markets
2.70
3.60
0.00
0.01
-
Leverage Ratio 1.40
ProfitabilityValueIndustryS&P 500US Markets
68.30
-39.40
-23.70
-493.70
-38.22
RevenueValueIndustryS&P 500US Markets
43.53M
1.86
112.50
72.41
Earnings HistoryEstimateReportedSurprise %
Q02 2021-0.50-0.476.00
Q01 2021-0.60-0.4033.33
Q03 2020-3.90-1.5061.54
Q02 2020-3.40-3.108.82
Q01 2020-3.00-3.20-6.67
Q04 2019-0.41-1.30-217.07
Q03 2019-0.61-0.5018.03
Q02 2019-0.35-0.72-105.71
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.3260.00Positive
6/2021 QR-0.37-85.00Negative
6/2021 FY-0.9320.51Positive
6/2022 FY-0.83-33.87Negative
Next Report Date13th May 2021
Estimated EPS Next Report-0.32
Estimates Count1
EPS Growth Next 5 Years %-
Volume Overview
Volume381.86K
Shares Outstanding17.88M
Trades Count3.08K
Dollar Volume3.47M
Avg. Volume701.70K
Avg. Weekly Volume351.56K
Avg. Monthly Volume526.44K
Avg. Quarterly Volume720.55K

Aytu BioScience Inc. (NASDAQ: AYTU) stock closed at 6.44 per share at the end of the most recent trading day (a -0.92% change compared to the prior day closing price) with a volume of 382.16K shares and market capitalization of 115.17M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 75 people. Aytu BioScience Inc. CEO is Joshua R. Disbrow.

The one-year performance of Aytu BioScience Inc. stock is -53.67%, while year-to-date (YTD) performance is 7.69%. AYTU stock has a five-year performance of -99.98%. Its 52-week range is between 5.86 and 21.3, which gives AYTU stock a 52-week price range ratio of 3.76%

Aytu BioScience Inc. currently has a PE ratio of -6.40, a price-to-book (PB) ratio of 1.35, a price-to-sale (PS) ratio of 3.50, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -18.00%, a ROC of -33.93% and a ROE of -33.98%. The company’s profit margin is -38.22%, its EBITDA margin is -23.70%, and its revenue ttm is $43.53 Million , which makes it $1.86 revenue per share.

Of the last four earnings reports from Aytu BioScience Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.32 for the next earnings report. Aytu BioScience Inc.’s next earnings report date is 13th May 2021.

The consensus rating of Wall Street analysts for Aytu BioScience Inc. is Strong Buy (1), with a target price of $17.4, which is +170.19% compared to the current price. The earnings rating for Aytu BioScience Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Aytu BioScience Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Aytu BioScience Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 14.85, ATR14 : 0.54, CCI20 : -119.48, Chaikin Money Flow : -0.04, MACD : -0.31, Money Flow Index : 26.65, ROC : -14.47, RSI : 42.76, STOCH (14,3) : 14.77, STOCH RSI : 0.02, UO : 44.25, Williams %R : -85.23), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Aytu BioScience Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (100.00 %)
2 (100.00 %)
2 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Aytu BioScience Inc.

Aytu BioScience Inc is a specialty pharmaceutical company commercializing novel products addressing patient needs. The company markets a portfolio of prescription products addressing large therapeutic markets. The primary care portfolio includes Natesto, the only FDA-approved nasal formulation of testosterone, ZolpiMist, the only FDA-approved oral spray prescription sleep aid, and Tuzistra XR, the only FDA-approved 12-hour codeine-based antitussive syrup. The pediatric portfolio includes AcipHex Sprinkle, Cefaclor, Karbinal ER, and Poly-Vi-Flor and Tri-Vi-Flor.

CEO: Joshua R. Disbrow

Telephone: +1 720 437-6580

Address: 373 Inverness Parkway, Englewood 80112, CO, US

Number of employees: 75

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

56%44%

Bearish Bullish

56%44%

Bearish Bullish

53%48%

News

Stocktwits